US 11,673,972 B2
Heterodimeric antibodies that bind CD3 and tumor antigens
Matthew J. Bernett, Monrovia, CA (US); Gregory Moore, Azusa, CA (US); John Desjarlais, Pasadena, CA (US); Seung Chu, Cypress, CA (US); Rumana Rashid, Temple City, CA (US); Umesh Muchhal, Monrovia, CA (US); and Sung-Hyung Lee, San Gabriel, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on Dec. 16, 2020, as Appl. No. 17/124,371.
Application 17/124,371 is a continuation of application No. 14/952,714, filed on Nov. 25, 2015, granted, now 10,889,653.
Claims priority of provisional application 62/251,005, filed on Nov. 4, 2015.
Claims priority of provisional application 62/250,971, filed on Nov. 4, 2015.
Claims priority of provisional application 62/159,111, filed on May 8, 2015.
Claims priority of provisional application 62/085,117, filed on Nov. 26, 2014.
Claims priority of provisional application 62/085,027, filed on Nov. 26, 2014.
Claims priority of provisional application 62/085,106, filed on Nov. 26, 2014.
Claims priority of provisional application 62/084,908, filed on Nov. 26, 2014.
Prior Publication US 2021/0102003 A1, Apr. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 7 Claims
 
1. A composition comprising an anti-CD3 antibody binding domain, said anti-CD3 binding domain comprising:
a) a variable light domain comprising a vlCDR1 having the sequence GSSTGAVTTSNYAN (SEQ ID NO: 15), a vlCDR2 having the sequence GTNKRAP (SEQ ID NO: 16), and a vlCDR3 having the sequence ALWYSNHWV (SEQ ID NO: 17); and
b) a variable heavy domain comprising a vhCDR1 having the sequence TYAMN (SEQ ID NO: 11), a vhCDR2 having the sequence RIRSKANNYATYYADSVKG (SEQ ID NO: 12) and a vhCDR3 having the sequence HGNFGDSYVSWFAY (SEQ ID NO: 13).